235.1 🎓 醫孞生版

235.1.0.1 📌 䞀頁重點

235.1.0.1.1 3 Main Pathogenic Free-Living Amebae
235.1.0.1.1.1 1. Naegleria fowleri (“Brain-Eating Ameba”)
  • Primary Amebic Meningoencephalitis (PAM)
  • Rapid fatal (mortality > 97%)
  • Warm freshwater swimming (pools, lakes, hot springs, neti pot)
  • Nasal entry → cribriform plate → olfactory bulbs → CNS
  • Rare (< 10 USA cases/yr; ~ 200 cases known worldwide)
  • 2024: climate change expanding range (more northern outbreaks)
235.1.0.1.1.2 2. Acanthamoeba spp.
  • Granulomatous Amebic Encephalitis (GAE) — chronic, in immunocompromise + AIDS
  • Acanthamoeba Keratitis — contact lens wearers, ocular
  • Cutaneous Acanthamoebiasis
  • Disseminated in immunocompromise
235.1.0.1.1.3 3. Balamuthia mandrillaris
  • GAE — similar to Acanthamoeba but also in immunocompetent
  • Subacute / chronic
  • Cutaneous + CNS
  • Rare globally
235.1.0.1.2 Naegleria fowleri (PAM)
235.1.0.1.2.1 Microbiology
  • Thermophilic amoeba (37-45°C ideal)
  • Trophozoite + flagellate (transient) + cyst forms
  • Worldwide in warm freshwater
235.1.0.1.2.2 Transmission
  • Diving / swimming in warm freshwater (lakes, hot springs, ponds, inadequately chlorinated pools)
  • Nasal irrigation with contaminated water (neti pot use) — sentinel cases
  • NOT person-to-person
235.1.0.1.2.3 Clinical (PAM)
  • 1-9 day incubation
  • Sudden onset:
    • Severe headache (frontal)
    • Fever
    • Stiff neck
    • Vomiting
    • Olfactory disturbance / loss
  • Progressive over 24-72 hr:
    • Altered mental status
    • Seizures
    • Cranial nerve palsies
    • Coma → death within 1-2 weeks
  • Mortality > 97%
235.1.0.1.2.4 Diagnosis
  • CSF examination: lymphocytic pleocytosis with some PMN, low glucose, high protein
  • CSF microscopy (wet mount, Giemsa): trophozoites
  • PCR of CSF + biopsy
  • MRI: meningitis, hemorrhage, basal cisterns
235.1.0.1.2.5 Treatment
  • Combination therapy (no proven single regimen):
    • Amphotericin B IV + intrathecal (high-dose)
    • Miltefosine PO (key drug, FDA accelerated 2013)
    • Azithromycin, fluconazole, rifampin
    • Dexamethasone
  • Therapeutic hypothermia (rare survivor cases)
  • < 10 documented survivors globally
  • 2024 +: ongoing investigational protocols
235.1.0.1.2.6 Prevention
  • Avoid swimming in warm freshwater during hot weather (Texas + Florida + Gulf states)
  • Plug or hold nose during freshwater activities
  • Use boiled / distilled water for neti pot / nasal irrigation
  • Don’t drink + don’t reuse untreated water
235.1.0.1.3 Acanthamoeba
235.1.0.1.3.1 Geography + Sources
  • Worldwide
  • Soil, water, dust, air conditioning, contact lens cases
235.1.0.1.3.2 Clinical Forms
  • GAE (Granulomatous Amebic Encephalitis)
    • Immunocompromise + HIV (CD4 < 200) primarily
    • Chronic / subacute course (weeks-months)
    • Focal neurological signs
    • Mass effect lesions
    • Mortality 90%+
  • Keratitis
    • Contact lens wearers (using contaminated water, poor lens hygiene, tap water rinse)
    • Severe corneal ulceration
    • Severe pain disproportionate
    • Vision loss if untreated
  • Cutaneous
    • Immunocompromise
    • Nodules + ulcers
  • Disseminated
    • Multi-organ
    • Immunocompromise
235.1.0.1.3.3 Diagnosis
  • Keratitis: corneal scraping + Giemsa / calcofluor white + culture + PCR
  • GAE: CSF + brain biopsy + PCR
  • Skin: biopsy + PCR
235.1.0.1.3.4 Treatment
235.1.0.1.3.5 Keratitis
  • Topical antiamebic combination: chlorhexidine + polyhexamethylene biguanide (PHMB) + propamidine + neomycin
  • Long course (months)
  • Surgery (corneal transplant) for severe / refractory
235.1.0.1.3.6 GAE / Disseminated
  • Miltefosine + combination (azole + sulfadiazine + macrolide + others)
  • Immune restoration (ART for HIV)
  • Mortality high
235.1.0.1.4 Balamuthia mandrillaris
235.1.0.1.4.1 Background
  • Identified 1990 (Mandrill baboon brain)
  • Worldwide soil + dust
  • Causes GAE + cutaneous in immunocompetent + immunocompromise
235.1.0.1.4.2 Clinical
  • Subacute / chronic GAE (weeks-months)
  • Headache, focal signs, mass lesions
  • Cutaneous lesions (often precede CNS)
  • Mortality 89%+
235.1.0.1.4.3 Diagnosis
  • Brain biopsy
  • Skin biopsy
  • PCR
235.1.0.1.4.4 Treatment
  • Miltefosine + combination (fluconazole + azithromycin + clarithromycin + 5-flucytosine + albendazole + nitroxoline)
  • Multi-drug; long course
235.1.0.1.5 Sappinia pedata + Diphylleia (Rare)
  • Single case reports
  • CNS

235.1.0.2 1⃣ Naegleria fowleri (PAM) Detail

235.1.0.2.1 Microbiology
  • Thermophilic free-living ameba
  • 37-45°C ideal (warm freshwater)
  • Trophozoite (motile invasive form), flagellate (swimming, transient), cyst (resistant)
  • Worldwide distribution
235.1.0.2.2 Transmission Specifics
  • Water enters nose (diving, swimming with head submerged)
  • Cribriform plate of ethmoid bone → olfactory bulbs → CNS
  • Neti pot outbreaks documented (use tap water with contamination)
  • Inadequately chlorinated pools, hot springs, splash pads
  • USA: Texas, Florida, Arizona + Gulf states; climate change expanding north
235.1.0.2.3 USA Cases
  • 1-10 cases/yr
  • Texas + Florida + Arizona + Louisiana most
  • Children + young males predominant (recreational water activity)
  • 2024+: northern cases (Minnesota, Indiana, Nebraska, etc.)
235.1.0.2.4 Clinical PAM (Primary Amebic Meningoencephalitis)
235.1.0.2.4.1 Incubation
  • 1-9 days
235.1.0.2.4.2 Acute Phase
  • Sudden onset severe headache (often frontal)
  • Fever
  • Nausea / vomiting
  • Olfactory disturbance / anosmia (key early clue)
  • Stiff neck
235.1.0.2.4.3 Progressive Phase (24-72 Hours)
  • Altered mental status
  • Seizures
  • Confusion → coma
  • Cranial nerve palsies
  • Photophobia
  • Cardiovascular collapse
235.1.0.2.4.4 Outcome
  • Death within 7-14 days of onset in > 97% of cases
  • < 10 documented survivors worldwide (since 1962 first cases)
  • Recent survivors (2013+, 2016+) — combination therapy + therapeutic hypothermia
235.1.0.2.5 Diagnosis
235.1.0.2.5.1 CSF
  • Lymphocytic pleocytosis with significant PMN (initially can be very PMN-dominant)
  • Low glucose (< 40 mg/dL often)
  • High protein
  • RBCs common (hemorrhagic)
  • Opening pressure elevated
235.1.0.2.5.2 CSF Microscopy
  • Wet mount of fresh CSF: motile trophozoites
  • Giemsa stain: trophozoites
  • Don’t refrigerate before examination (kills trophozoites)
  • Hemorrhagic CSF in many
235.1.0.2.5.3 PCR
  • CSF + brain biopsy
  • Most sensitive
  • Reference labs (CDC)
235.1.0.2.5.4 Imaging
  • MRI: basal cistern enhancement, meningitis, hemorrhage
  • May be normal early
  • Cerebral edema common
235.1.0.2.5.5 Differential
  • Bacterial meningitis
  • Viral encephalitis (HSV, others)
  • Cryptococcal meningitis
  • TB meningitis
235.1.0.2.6 Treatment (Combination)
  • Amphotericin B IV (high-dose) + intrathecal (lifesaving combination)
  • Miltefosine PO (FDA accelerated approval 2013; key oral agent)
  • Azithromycin (combination)
  • Fluconazole / voriconazole (combination)
  • Rifampin (combination)
  • Dexamethasone (steroid for edema)
  • Therapeutic hypothermia (some survivor cases)
  • ICU + ventilator + supportive
  • CDC consultation 24/7 hotline for treatment guidance
235.1.0.2.7 Recent Survivors
  • 2013 Texas case (Kali Hardig): combination Tx + hypothermia
  • 2016 Florida case (Sebastian DeLeon): combination Tx + hypothermia
  • 2018 Texas case
  • 2024 ongoing cases
  • Survival rate: < 3% overall, but increasing with awareness + new protocols
235.1.0.2.8 Prevention
  • Avoid diving / underwater swimming in warm freshwater during hot weather
  • Use nose clip or hold nose
  • Neti pot: boiled or distilled water only (not tap water)
  • Don’t drink + irrigate eyes with untreated water
  • Pool maintenance + chlorination
  • Public health warnings

235.1.0.3 2⃣ Acanthamoeba

235.1.0.3.1 Geography + Sources
  • Worldwide in soil, water, dust, AC systems
  • Contact lens cases + tap water = major exposure for keratitis
  • Also: hot tubs, swimming pools, soil contact
235.1.0.3.2 Forms
  • Trophozoite (motile)
  • Cyst (very resistant)
235.1.0.3.3 Clinical Forms
235.1.0.3.3.1 Acanthamoeba Keratitis
  • Risk factors:
    • Contact lens wearers (especially extended-wear soft contacts, swimming with lens, tap water rinse)
    • Corneal trauma
    • Poor lens hygiene
  • Clinical:
    • Severe ocular pain (disproportionate to findings)
    • Photophobia
    • Foreign body sensation
    • Decreased visual acuity
    • Ring corneal infiltrate characteristic
    • Pseudo-dendritic ulcer (mimics HSV)
  • Diagnosis often delayed
  • Severe vision threat
  • Confocal microscopy increasingly used
235.1.0.3.3.2 Granulomatous Amebic Encephalitis (GAE)
  • Immunocompromise primarily (HIV, transplant, anti-TNF)
  • Subacute / chronic (weeks-months)
  • Focal neurological signs, headache, seizures
  • Mass lesions on MRI
  • High mortality
235.1.0.3.3.3 Cutaneous Acanthamoebiasis
  • Immunocompromise
  • Nodules, ulcers
  • Disseminated potential
235.1.0.3.3.4 Disseminated
  • Multi-organ
  • Mortality high
235.1.0.3.4 Diagnosis
235.1.0.3.4.1 Keratitis
  • Corneal scraping for:
    • Giemsa / hematoxylin stain
    • Calcofluor white (fluorescent stain) — cysts
    • Culture on non-nutrient agar with E. coli lawn
    • PCR
  • Confocal microscopy
  • High index of suspicion (often misdiagnosed as HSV initially)
235.1.0.3.4.2 GAE / Disseminated
  • CSF microscopy / PCR
  • Brain biopsy + PCR + IHC
  • Skin biopsy
235.1.0.3.5 Treatment
235.1.0.3.5.1 Keratitis
  • Topical combination antiamebic:
    • Chlorhexidine 0.02% or polyhexamethylene biguanide (PHMB) 0.02% (cyst-killing)
    • Propamidine 0.1% (Brolene) or hexamidine (trophozoite-killing)
    • Neomycin (broad antibacterial)
  • Long course (3-12 months)
  • Topical steroid carefully (controversial; mostly avoided)
  • Penetrating keratoplasty for refractory + visual impairment
  • Visual outcomes variable; many require corneal transplant
235.1.0.3.5.2 GAE / Disseminated
  • Miltefosine (oral)
  • Combination: fluconazole + sulfadiazine + azithromycin / clarithromycin + flucytosine + pentamidine
  • Long course
  • Mortality high (90%+)
  • ART for HIV
235.1.0.3.6 Prevention
  • Contact lens hygiene:
    • No tap water rinse
    • Use sterile saline / proper solution
    • No swimming with lens
    • Don’t extend wear time
  • Sterile contact lens solution storage
  • Avoid sleeping in lenses

235.1.0.4 3⃣ Balamuthia mandrillaris

235.1.0.4.1 Background
  • Identified 1990 (mandrill baboon brain)
  • Worldwide soil + dust
  • Particularly cases in immigrant Hispanic populations USA
  • Soil contact + water exposure
235.1.0.4.2 Forms
  • Trophozoite + cyst
  • Slow-growing in culture
235.1.0.4.3 Clinical
235.1.0.4.3.1 GAE
  • Immunocompetent + immunocompromise (unlike Acanthamoeba)
  • Subacute / chronic (weeks-months-years)
  • Headache, seizures, focal neuro signs
  • Mass lesions on MRI
  • Brainstem + spinal involvement possible
235.1.0.4.3.2 Cutaneous
  • Often precedes CNS (months-years)
  • Painless skin lesion or plaque
  • Face, knees, legs typical
  • Slowly enlarging
  • Can spread hematogenously to CNS
235.1.0.4.3.3 Disseminated
  • Lungs, liver, etc.
  • Multi-organ
235.1.0.4.4 Diagnosis
  • Brain biopsy (often only definitive)
  • Skin biopsy with PCR
  • CSF rarely positive
  • Slow culture
  • PCR sensitivity emerging
235.1.0.4.5 Treatment
  • Miltefosine + combination:
    • Fluconazole
    • Azithromycin / clarithromycin
    • 5-flucytosine
    • Albendazole
    • Nitroxoline (emerging)
    • Pentamidine sometimes
  • Multi-drug long course (months)
  • Mortality 89%+
  • Earlier diagnosis improves outcome

235.1.0.5 4⃣ Treatment Considerations

235.1.0.5.1 Miltefosine
  • Key drug for all 3 free-living amebae (Naegleria, Acanthamoeba, Balamuthia)
  • FDA accelerated approval 2013 for free-living amebae
  • Available via CDC for compassionate use
  • Mechanism: cell membrane disruption + apoptosis
  • Toxicity: GI, hepatic, teratogenic (pregnancy contraindicated)
  • Long half-life
235.1.0.5.2 CDC Consultation
  • 24/7 hotline for suspected free-living ameba infections
  • Treatment guidance
  • Miltefosine acquisition
235.1.0.5.3 Survivors of PAM (Lessons)
  • Aggressive combination therapy early
  • Therapeutic hypothermia in some
  • Targeted treatment as soon as suspected — don’t wait for confirmation
  • Public awareness + faster recognition